Clinical Trials Browser

NCT05775939 2026-02-10

PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial

Phase NA Recruiting

20 enrolled

GastrointestinalThoracic

Esophageal Neoplasms, Lung Neoplasms

NCT04147494 2025-08-12

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

Phase EARLY_PHASE1 Active not recruiting

29 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT07118176 2025-08-12

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Phase 1 Recruiting

30 enrolled

BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETSarcomaThoracic

Adrenal Gland Neoplasms, Anus Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Penile Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Stomach Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Colorectal Neoplasms, Carcinoma, Medullary, Cholangiocarcinoma, Neuroendocrine Tumors, Solitary Fibrous Tumors

Clinical Trials

PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients

Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy

Multimodalitic Imaging in the N-stage of Lung Cancer

PD-L2 Targeting Nanobody Radiotracer for PET Imaging of Solid Tumor

18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules

Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy

Methylprednisolone Before Fludeoxyglucose-Labeled Positron Emission Tomography in Patients With Lung Cancer

Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed by Surgery

Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Positron Emission Tomography for Detecting Non-small Cell Lung Cancer

The Role of Audiovisual Biofeedback on Image Quality During 4D Anatomic and Functional Imaging

68Ga-AlfatideII for the Differential Diagnosis of of Lung Cancer and Lung Tuberculosis by PET/CT

Pilot Study of 18F-FAZA in Assessing Early Functional Response in Patients With Inoperable Non Small Cell Lung Cancer Undergoing Radiotherapy or Chemo-radiotherapy

PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery

11C Topotecan PET Imaging

FDG-PET lung